Miracle completed the merger and acquisition of Hongguang Pharmaceutical Co., Ltd. in Nanxi District of Yibin City in 2018. Hongguang Company is a new pharmaceutical enterprise mainly focusing on R&D, production and sales of raw materials. Its predecessor is Yibin Hongguang Pharmaceutical Factory, which belongs to the subsidiary company of China Weapons Industry Group. Founded in 1998, the company passed the national drug GMP certification for the first time in 2001, and then passed the GMP certification again in 2005, 2009 and 2017, respectively. The company covers an area of 16,000 square meters and is located in Luolong Industrial Park, Yibin City, on the shore of the Yangtze River, with convenient transportation conditions.
The company's current product approval documents include:
lomefloxacin hydrochloride (Chinese medicine quasi-character H19991044),
cetirizine hydrochloride (Chinese medicine quasi-word H20010075),
doxazosin mesylate (Chinese medicine quasi-word H20010256),
pazufloxacin mesylate (Chinese medicine quasi-word H20041584), etc.
Relying on the comprehensive strength of scientific research and mass production, Miracle will continue to devote itself to the R&D and production of APIs and strive to become an important production base for contract processing outsourcing at home and abroad.